Newark, New Castle, USA, Feb. 01, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global dermatitis drugs market is expected to clock US$ 19.77 billion by 2030 and to grow at a CAGR of 14.60% during the forecast period. This exclusive information is published by Growth Plus Reports in its report titled “Dermatitis Drugs Market – Global Outlook & Forecast 2022-2030”
Increasing research and development activities are resulting in the introduction of novel drugs is a key trend propelling the growth of the global dermatitis drugs market. For instance, JAK (Janus) kinase inhibitors can stop JAK proteins. These substances trigger the release of chemicals that inflame the skin in dermatitis. Many JAK inhibitors are still in late-stage clinical trials. Research shows that JAK inhibitors can help clear the skin and reduce the itch.
Download PDF Brochure of Dermatitis Drugs Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.growthplusreports.com/inquiry/request-sample/dermatitis-drugs-market/8070
Market Drivers
The primary factor driving the global market for dermatitis drugs is the increasing prevalence of dermatitis. Additionally, due to the increased use of Interleukin -4 inhibitors like dipilumab, marketed under the brand names dupixent by Sanofi and Regeneron Pharmaceuticals, Eucrisa by Ancor Pharmaceuticals, the market for dermatitis treatments has seen significant expansion.
Excerpts from ‘by Drug Class’
The global market for dermatitis medications is divided into four categories based on the drug class:
- Biologics
- PDE4 inhibitors
- Corticosteroids
- Calcineurin Inhibitors
Since corticosteroids are the primary treatment for dermatitis, they hold the largest market share. Corticosteroids can simulate the effects of hormones. Additionally, corticosteroids decrease immune system activation, which is beneficial in vasoconstriction, which causes the blood vessels to constrict, eventually reducing inflammation. Other segments, such as biologics offer specific targeted therapy that does not interfere with the whole system; hence it offers few side effects than other treatments.
Excerpts from ‘By Disease Type’
According to disease type, the global dermatitis drugs market is grouped into:
- Atopic Dermatitis
- Contact Dermatitis
Atopic dermatitis has dominated the market. It is among the most prevalent types of dermatitis. Increased discovery for effective treatments and an increase in disease prevalence, and improved disease diagnostics have all contributed to the growth in atopic dermatitis. Additionally, according to JAAD International (The Journal of the American Academy of Dermatology), in 2019, atopic dermatitis affected almost 2.4% of the global population. The contact dermatitis segment is expected to progress steadily due to the moderately growing incidence. Contact dermatitis drugs witnessed a spike in demand during the COVID-19 pandemic due to the allergic reaction developed in the population owing to frequent hand-washing followed during the period.
Excerpts from ‘By Distribution Channel’
Based on the types of distribution channels, the global dermatitis drugs market has been segmented into:
- Hospitals
- Aesthetic Centers
- Pharmacies
Among these, pharmacies account for the largest revenue share of the global dermatitis market and shall continue to maintain its lead through the forecast period. The widespread presence of retail pharmacies and greater uptake of OTC topical drugs for dermatitis treatment drive the pharmacy segment growth. Furthermore, growing awareness in emerging markets will support the high growth rate of aesthetic clinics in Asia Pacific and Latin America markets.
Browse detail report and full TOC: https://www.growthplusreports.com/report/dermatitis-drugs-market/8070
Excerpts from ‘By Region’
The global dermatitis drugs market has been divided into four regions:
- North America
- Europe
- Asia Pacific
- Rest of the World
The North American region has dominated the global market. The growth of this region is attributed to increased healthcare spending, rising research and development, and increased incidences of dermatitis. The European market is characterized by improved healthcare spending, a rise in government funding for research, and an increased prevalence of dermatitis. The Asia Pacific region is accepted to rise during the forecast period due to the rising healthcare financing, growing public awareness, and a sizable patient population, which will eventually increase in clinical trials in the region.
Excerpts from ‘Competitive Landscape’
Some of the prominent players operating in the dermatitis drugs market are:
- Bayer AG
- LEO Pharma A/S
- Pfizer Inc.
- Sanofi SA
- Mylan N.V.
- Allergan Inc.
- Anacor Pharmaceuticals Inc.
- Regeneron Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Teva Pharmaceuticals Industries Ltd.
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years – 2020
- Base Year – 2021
- Forecasted Years – 2022 to 2031
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trends (COVID-19 Perspective)
- Key Players & Competitive Positioning (2021)
- MARKET DYNAMICS
- Drivers
- Restraints
- Opportunities
- GLOBAL DERMATITIS DRUGS MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
- Biologics
- PDE4 Inhibitors
- Corticosteroids
- Calcineurin Inhibitors
- GLOBAL DERMATITIS DRUGS MARKET - ANALYSIS & FORECAST, BY DISEASE TYPE
- Atopic Dermatitis
- Contact Dermatitis
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Buy now complete report here: https://www.growthplusreports.com/checkout-8070
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
